At MediRedox, our core technology is built upon decades of pioneering research into APE1/Ref-1. Our proprietary methods and therapeutic strategies are rigorously validated by high-impact, peer-reviewed publications. We bridge the gap between molecular discovery and life-saving patient care. 

1. Clinical Diagnostics & Biomarkers Utilizing plasma APE1/Ref-1 to detect diseases and predict clinical outcomes. Tracking expression shifts to guide diagnostics and monitor treatment efficacy.

2. Inflammation & Organ Protection Protecting against systemic inflammation, oxidative stress, and fibrosis. Suppressing ROS pathways to prevent drug-induced organ damage.

3. Breakthroughs in Refractory Cancers Targeting APE1/Ref-1 to induce apoptosis in challenging malignancies. Combining acetylsalicylic acid with recombinant APE1/Ref-1 for TNBC and ovarian cancer.

Since 2018, our extensive research has been the foundation of our precision and reliability, driving our mission to transform global healthcare.